Back to discover

Protein / target

Mu-type opioid receptor

Encoded byOPRM1P35372Homo sapiensSwiss-Prot
Clinically validated
Therapeutic maturity
72
Approved medicines
Open Targets target-level
View by indication →
30
Clinical trials
Small-molecule tractable
Druggability
Approved Drug

Protein at a glance

Biological role

Voltage-gated calcium channel

Strongest disease association

Opioid-Related Disorders

Via encoding gene OPRM1 · Genetic evidence · score 0.84

Therapeutic position

Established drug target

Small molecules

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Receptor for endogenous opioids such as beta-endorphin and endomorphin.

View complete UniProt function annotation

Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478, PubMed:12589820, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed:10529478, PubMed:10836142, PubMed:12589820, PubMed:19300905, PubMed:7891175, PubMed:7905839, PubMed:7957926, PubMed:9689128). Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G protein complex and subsequent exchange of GDP for GTP in the G protein alpha subunit leading to dissociation of the G protein complex with the free GTP-bound G protein alpha and the G protein beta-gamma dimer activating downstream cellular effectors (PubMed:7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed:12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G protein-coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity)

Subcellular location

Cell membraneCell projection, axonPerikaryonCell projection, dendriteEndosomeCytoplasm
Domains and Gene Ontology detail (34)

Gene Ontology

  • Caxon
  • Cdendrite
  • Cendoplasmic reticulum
  • Cendosome
  • CGolgi apparatus
  • Cneuron projection
  • Cperikaryon
  • Cplasma membrane
  • Csynapse
  • Fbeta-endorphin receptor activity
  • FG protein-coupled receptor activity
  • FG-protein alpha-subunit binding

400 aa · 45 kDa · 18 isoforms

Biological roles

Reactome v97

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOG protein-coupled signallingUniProt · GO
View supporting evidence

Cell proliferation & survival

  • ·negative regulation of cell population proliferation

G protein-coupled signalling

  • ·Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed:10529478,…
  • ·G protein-coupled receptor activity
  • ·adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway
  • ·adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
View underlying pathways (6)

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Interaction neighbourhood

STRING v12.0

Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.

PENKPOMCGNAI1PDYNARRB2ARRB1OPRD1GRK2GRK6GRK5OPRM1

10 strongest partners — larger node and heavier line mean higher confidence

Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.

Approved medicines with mapped indications

5 medicines · 11 areas

Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.

Chronic Pain3 medicines
Acute Pain2 medicines
Substance-Related Disorders2 medicines
Alcoholism1 medicine
Cancer Pain1 medicine
Diarrhea1 medicine
Drug Overdose1 medicine
Irritable Bowel Syndrome1 medicine
Opioid-Related Disorders1 medicine
Broader indication categories (1)
Neoplasms1 medicine

Broad umbrella indications (e.g. “Neoplasms”). Shown here because every medicine also appears under a more specific disease above — kept for completeness, de-emphasised for clarity.

72 medicines meet Open Targets' target-level approved-medicine definition; the 5 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.

Drugs targeting this protein

6

How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.

Fentanyl
Narrow target profileApprovedAgonist

Mu opioid receptor agonist

Indicated for Acute Pain, Cancer Pain, Chronic Pain, Pain

Direct interaction with this protein · Only this protein recorded as a target

Buprenorphine
Narrow target profileApprovedAgonist

Mu opioid receptor agonist

Indicated for Acute Pain, Chronic Pain, Drug Overdose, Opioid-Related Disorders

Direct interaction with this protein · 1 of 2 recorded protein targets — narrow recorded profile

Oxycodone
Narrow target profileApprovedAgonist

Mu opioid receptor agonist

Indicated for Chronic Pain, Pain, Substance-Related Disorders

Direct interaction with this protein · Only this protein recorded as a target

Heroin
Narrow target profileAgonist

Mu opioid receptor agonist

Direct interaction with this protein · Only this protein recorded as a target

eluxadoline
Narrow target profileApprovedAgonist

Mu opioid receptor agonist

Indicated for Diarrhea, Irritable Bowel Syndrome

Direct interaction with this protein · Only this protein recorded as a target

Naltrexone
ApprovedAntagonist

Opioid receptors; mu/kappa/delta antagonist

Indicated for Alcoholism

Acts on a complex — shared with OPRK1, OPRD1 · 1 of 3 recorded protein targets — narrow recorded profile

ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene OPRM1

Gene-level evidence surfaced through the gene OPRM1 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Opioid-Related Disorders
0.96Well supported

Genetic evidence dominant · Open Targets 0.69

Neoplasms
0.76Well supported

Clinical evidence dominant · Open Targets 0.62

Alcoholism
0.76Well supported

Clinical evidence dominant · Open Targets 0.61

Migraine Disorders
0.74Moderately supported

Clinical evidence dominant · Open Targets 0.60

View evidence synthesis (4)
Opioid-Related DisordersWell supported
0.96
agreement 0.851.00
Genetic51%Clinical45%Literature3%

Open Targets aggregate 0.69 · 3 independent evidence families

NeoplasmsWell supported
0.76
agreement 0.610.92
Clinical85%Literature15%

Open Targets aggregate 0.62 · 2 independent evidence families

AlcoholismWell supported
0.76
agreement 0.600.91
Clinical92%Literature8%

Open Targets aggregate 0.61 · 2 independent evidence families

Migraine DisordersModerately supported
0.74
agreement 0.580.89
Clinical96%Literature4%

Open Targets aggregate 0.60 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Opioid-Related Disorders0.69
Neoplasms0.62
Alcoholism0.61
Migraine Disorders0.60

Drug development

88 compounds recorded · 72 approved · 16 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines. Distinct from the 6 drugs that target this protein in Forefront's canonical graph (5 with a mapped approved indication, shown above): these count different sets and are not a subset relation.

View all recorded compounds (10)
MEPERIDINE HYDROCHLORIDEApproval
HYDROCODONEApproval
NALOXONE HYDROCHLORIDE DIHYDRATEApproval
NALOXEGOLApproval
NALOXEGOL OXALATEApproval
METHYLNALTREXONEPhase 3
CEBRANOPADOLPhase 3
FENTANYLApproval
LEVALLORPHANApproval
MEPERIDINEApproval

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small moleculesStrong

Approved Drug and Structure with Ligand support this modality.

AntibodiesEmerging

Feasibility evidence (uniprot loc high conf and go cc high conf) — no clinical-stage drug of this modality recorded.

Protein degradersEmerging

Feasibility evidence (uniprot ubiquitination and small molecule binder) — no clinical-stage drug of this modality recorded.

Other modalitiesStrong

Advanced Clinical support this modality.

View underlying tractability evidence (10)
SM · Approved DrugSM · Structure with LigandSM · High-Quality LigandSM · Druggable FamilyAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMPR · UniProt UbiquitinationPR · Small Molecule BinderOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Safety-related annotations

quality of sleepClinPGxnicotine dependenceClinPGxneurotoxicityClinPGxdecreased gastric emptyingLynch et al. (2017)decreased anxietyLynch et al. (2017)opioid-induced adverse effects, opioid-induced nausea and vomitingClinPGxgasLynch et al. (2017)decreased gastrointestinal transitLynch et al. (2017)treatment emergent suicidal ideation (TESI)ClinPGxsleep apneaClinPGxdecreased cardiac outputLynch et al. (2017)decreased gastrointestinal motilityBowes et al. (2012)

Terms indexed against this target in Open Targets' safety data, with their datasource. These are annotations, not causal claims: the direction of effect (whether activation or inhibition is implicated), species and evidence strength are not captured here, so an entry does not mean that modulating this target is known to cause that condition.

Clinical trials

30

Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.

View all trials (26)

RECRUITING · via Oxycodone · NCT07348627

NOT_YET_RECRUITING · via Fentanyl · NCT06531759

COMPLETED · via Fentanyl · NCT07238101

ClinicalTrials.gov via the drug-target graph.

What's happening now

12

Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 6 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.

  1. Trial status changed2026-08-25

    Dose-Effect Relationship of Dexmedetomidine on Delirium and Cognitive Function After Lower Limb Orthopedic Surgeries for Elderly Patients

    Status changed to Completed · ClinicalTrials.gov · via Fentanyl

  2. Supplemental approval2026-08-14

    Supplemental approval: BUPRENORPHINE (ANDA078633)

    fda · regulatory · fda · via Buprenorphine

  3. Supplemental approval2026-08-14

    Supplemental approval: BUPRENORPHINE (ANDA090819)

    fda · regulatory · fda · via Buprenorphine

  4. Supplemental approval2026-08-14

    Supplemental approval: BUPRENORPHINE (ANDA201760)

    fda · regulatory · fda · via Buprenorphine

  5. Supplemental approval2026-08-14

    Supplemental approval: BUPRENORPHINE (ANDA207276)

    fda · regulatory · fda · via Buprenorphine

  6. Trial status changed2026-08-14

    Development of Variable Volume Automated Mandatory Boluses (VVAMB) for Patient-controlled Epidural Analgesia During Labour and Delivery

    Status changed to Active, not recruiting · ClinicalTrials.gov · via Fentanyl

  7. Trial status changed2026-08-07

    A Comparison Between the Effect of Ketamine-lidocaine Versus Ketamine-fentanyl for Induction of Anesthesia on Cerebral Perfusion Guided by Near Infra-red Spectroscopy in Patients With Coronary Artery Disease and Left Ventricular Systolic Dysfunction Undergoing Elective Coronary Artery Bypass Graft Surgery: (A Randomized Controlled Study)

    Status changed to Completed · ClinicalTrials.gov · via Fentanyl

  8. New publication2025-04-30
    Supervised and unsupervised learning reveal heroin-induced impairments in astrocyte structural plasticity.

    Science advances · 2025 · 5 citations · Europe PMC · via Heroin

  9. New publication2024-10-29
    The Role of Acid-Sensing Ion Channel 1A (ASIC1A) in the Behavioral and Synaptic Effects of Oxycodone and Other Opioids.

    International journal of molecular sciences · 2024 · 6 citations · Europe PMC · via Oxycodone

  10. New publication2024-01-25
    Opioid use disorder: current trends and potential treatments.

    Frontiers in public health · 2023 · 24 citations · Europe PMC · via Buprenorphine

  11. New publication2023-09-26
    Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.

    Obesity (Silver Spring, Md.) · 2023 · 40 citations · Europe PMC · via Naltrexone

  12. Safety communication2017-12-14

    Drug Safety Update: Eluxadoline (Truberzi▼): risk of pancreatitis; do not use in patients who have undergone cholecystectomy or in those with biliary disorders

    mhra · safety · mhra · via eluxadoline

Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.